Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP-1 Receptor Agonist Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. | #aanpak
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP-1 Receptor Agonist Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. | #aanpak